AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:54:00Z
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Fri 18 Oct 24, 02:00 PMWhy We Like The Returns At HCA Healthcare (NYSE:HCA)
Fri 18 Oct 24, 01:00 PMAcadia Healthcare Ventures in South Carolina With Three Buyouts
Wed 16 Oct 24, 05:03 PMHere's Why You Should Add Elevance Health Stock to Your Portfolio
Wed 09 Oct 24, 05:05 PMHCA Healthcare, Inc. (HCA): A Buzzing AI Health Stock to Add to Your Portfolio
Sat 05 Oct 24, 01:24 PMCompelling Reasons to Hold on to Encompass Health Stock Right Now
Fri 04 Oct 24, 05:32 PMEnsign Expands Presence in Nebraska With Two Acquisitions
Thu 03 Oct 24, 04:14 PMCan Tenet Healthcare's $910M Divestment in Alabama Cure its Debt Woes?
Wed 02 Oct 24, 02:04 PMWhy This 1 Medical Stock Could Be a Great Addition to Your Portfolio
Tue 01 Oct 24, 01:30 PM7 Best Dialysis and Kidney Disease Stocks to Buy
Sat 28 Sep 24, 05:21 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8580.00M | 9833.00M | 5430.00M | 5244.00M | 5335.00M |
| Minority interest | -1191.00000M | -765.00000M | 633.00M | 640.00M | 602.00M |
| Net income | 5643.00M | 6956.00M | 3754.00M | 3505.00M | 3787.00M |
| Selling general administrative | 27685.00M | 26779.00M | 23874.00M | 23560.00M | 21425.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 50862.00M | 49271.00M | 43164.00M | 42855.00M | 38953.00M |
| Reconciled depreciation | 2969.00M | 2853.00M | 2721.00M | 2596.00M | 2278.00M |
| Ebit | 9098.00M | 9791.00M | 7316.00M | 7261.00M | 6671.00M |
| Ebitda | 12067.00M | 12644.00M | 10037.00M | 9857.00M | 8949.00M |
| Depreciation and amortization | 2969.00M | 2853.00M | 2721.00M | 2596.00M | 2278.00M |
| Non operating income net other | 1268.00M | 1721.00M | -248.00000M | -150.00000M | 448.00M |
| Operating income | 9098.00M | 9791.00M | 7316.00M | 7261.00M | 6642.00M |
| Other operating expenses | 51180.00M | 49074.00M | 44271.00M | 44118.00M | 40035.00M |
| Interest expense | 1741.00M | 1566.00M | 1584.00M | 1824.00M | 1755.00M |
| Tax provision | 1746.00M | 2112.00M | 1043.00M | 1099.00M | 946.00M |
| Interest income | 1696.00M | 1453.00M | 1530.00M | 1781.00M | 1726.00M |
| Net interest income | -1741.00000M | -1566.00000M | -1584.00000M | -1824.00000M | -1755.00000M |
| Extraordinary items | - | - | - | - | 551.00M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1746.00M | 2112.00M | 1043.00M | 1099.00M | 946.00M |
| Total revenue | 60233.00M | 58752.00M | 51533.00M | 51336.00M | 46677.00M |
| Total operating expenses | 41809.00M | 39593.00M | 35902.00M | 35637.00M | 32311.00M |
| Cost of revenue | 9371.00M | 9481.00M | 8369.00M | 8481.00M | 7724.00M |
| Total other income expense net | -518.00000M | 42.00M | -1886.00000M | -2017.00000M | 448.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6834.00M | 7721.00M | 4387.00M | 4145.00M | 4389.00M |
| Net income applicable to common shares | 5643.00M | 6956.00M | 3754.00M | 3505.00M | 3787.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 52438.00M | 50742.00M | 47490.00M | 45058.00M | 39207.00M |
| Intangible assets | 9653.00M | 9540.00M | 8578.00M | 8269.00M | 7953.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1776.00M | 2010.00M | 1464.00M | 1346.00M | 1190.00M |
| Total liab | 52511.00M | 49253.00M | 44598.00M | 45623.00M | 42125.00M |
| Total stockholder equity | -2767.00000M | -933.00000M | 572.00M | -2808.00000M | -4950.00000M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5293.00M | 5234.00M | 4960.00M | 4707.00M | 3896.00M |
| Common stock | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Capital stock | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Retained earnings | -2280.00000M | -532.00000M | 777.00M | -2351.00000M | -4572.00000M |
| Other liab | 3143.00M | 3574.00M | 3426.00M | 2783.00M | 2460.00M |
| Good will | 9653.00M | 9540.00M | 8578.00M | 8269.00M | 7953.00M |
| Other assets | 298.00M | 598.00M | 546.00M | 480.00M | 690.00M |
| Cash | 908.00M | 1451.00M | 1793.00M | 621.00M | 502.00M |
| Cash and equivalents | 908.00M | 1451.00M | 1793.00M | 621.00M | 502.00M |
| Total current liabilities | 9902.00M | 9582.00M | 8704.00M | 7757.00M | 7569.00M |
| Current deferred revenue | - | - | - | - | 308.00M |
| Net debt | 38928.00M | 34883.00M | 30884.00M | 34600.00M | 32319.00M |
| Short term debt | 370.00M | 237.00M | 209.00M | 145.00M | 788.00M |
| Short long term debt | 370.00M | 237.00M | 209.00M | 145.00M | 788.00M |
| Short long term debt total | 39836.00M | 36334.00M | 32677.00M | 35221.00M | 32821.00M |
| Other stockholder equity | 2767.00M | 933.00M | 294.00M | 2243.00M | 2032.00M |
| Property plant equipment | 27640.00M | 26176.00M | 23199.00M | 22715.00M | 19757.00M |
| Total current assets | 13643.00M | 13542.00M | 12333.00M | 11196.00M | 10213.00M |
| Long term investments | 1204.00M | 886.00M | 810.00M | 564.00M | 594.00M |
| Net tangible assets | -10668.00000M | -10473.00000M | -6333.00000M | -9578.00000M | -12903.00000M |
| Short term investments | 381.00M | 438.00M | 388.00M | 147.00M | 47.00M |
| Net receivables | 8891.00M | 8095.00M | 7051.00M | 7380.00M | 6789.00M |
| Long term debt | 37714.00M | 34342.00M | 30795.00M | 33577.00M | 32033.00M |
| Inventory | 2068.00M | 1986.00M | 2025.00M | 1849.00M | 1732.00M |
| Accounts payable | 4239.00M | 4111.00M | 3535.00M | 2905.00M | 2577.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 2694.00M | 2422.00M | 2320.00M | 2243.00M | 2032.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -490.00000M | -404.00000M | -502.00000M | -460.00000M | -381.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -2280.00000M | -532.00000M | 777.00M | -2351.00000M | -4572.00000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 298.00M | 598.00M | 546.00M | 480.00M | 690.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 38795.00M | 37200.00M | 35157.00M | 33862.00M | 28994.00M |
| Capital lease obligations | 1752.00M | 1755.00M | 1673.00M | 1849.00M | - |
| Long term debt total | 37714.00M | 34342.00M | 30795.00M | 33577.00M | 32033.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -3389.00000M | -117.00000M | -588.00000M | -1657.00000M | -1196.00000M |
| Change to liabilities | -296.00000M | 999.00M | 1255.00M | 396.00M | 698.00M |
| Total cashflows from investing activities | -3389.00000M | -2643.00000M | -3393.00000M | -5720.00000M | -3901.00000M |
| Net borrowings | 3234.00M | 3255.00M | -3252.00000M | 494.00M | -369.00000M |
| Total cash from financing activities | -5656.00000M | -6655.00000M | -4677.00000M | -1771.00000M | -3075.00000M |
| Change to operating activities | - | - | - | - | - |
| Net income | 6834.00M | 7721.00M | 4387.00M | 4145.00M | 4389.00M |
| Change in cash | -543.00000M | -342.00000M | 1172.00M | 119.00M | -230.00000M |
| Begin period cash flow | 1451.00M | 1793.00M | 621.00M | 502.00M | 732.00M |
| End period cash flow | 908.00M | 1451.00M | 1793.00M | 621.00M | 502.00M |
| Total cash from operating activities | 8522.00M | 8959.00M | 9232.00M | 7602.00M | 6761.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 2969.00M | 2853.00M | 2721.00M | 2596.00M | 2278.00M |
| Other cashflows from investing activities | 1006.00M | -4.00000M | 30.00M | 95.00M | 868.00M |
| Dividends paid | -653.00000M | -624.00000M | -153.00000M | -550.00000M | 487.00M |
| Change to inventory | -59.00000M | -540.00000M | -304.00000M | -158.00000M | -242.00000M |
| Change to account receivables | -797.00000M | -962.00000M | 327.00M | -326.00000M | -423.00000M |
| Sale purchase of stock | -7000.00000M | -8215.00000M | -441.00000M | -1031.00000M | -1530.00000M |
| Other cashflows from financing activities | 4827.00M | -1071.00000M | -866.00000M | -757.00000M | -714.00000M |
| Change to netincome | -158.00000M | -374.00000M | 816.00M | 919.00M | 30.00M |
| Capital expenditures | 4395.00M | 3577.00M | 2835.00M | 4158.00M | 3573.00M |
| Change receivables | -797.00000M | -962.00000M | 327.00M | -326.00000M | -423.00000M |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -523.00000M | -339.00000M | 1162.00M | 111.00M | -215.00000M |
| Change in working capital | -1152.00000M | -503.00000M | 1278.00M | -88.00000M | 33.00M |
| Stock based compensation | 341.00M | 440.00M | 362.00M | 347.00M | 268.00M |
| Other non cash items | -1041.00000M | -1482.00000M | 443.00M | 352.00M | -281.00000M |
| Free cash flow | 4127.00M | 5382.00M | 6397.00M | 3444.00M | 3188.00M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HCA HCA Holdings Inc |
0.82 0.27% | 299.97 | 13.19 | 13.66 | 1.13 | 293.44 | 1.77 | 8.22 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.09 1.01% | 8.82 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| FSNUF Fresenius SE & Co. KGaA |
- -% | 34.66 | 16.76 | 9.62 | 0.42 | 0.79 | 0.78 | 5.31 |
| JDHIY JD Health International Inc |
- -% | 3.81 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
| JDHIF JD Health International Inc |
- -% | 3.12 | 57.75 | 32.68 | 0.29 | 2.11 | 0.16 | 3.90 |
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
One Park Plaza, Nashville, TN, United States, 37203
| Name | Title | Year Born |
|---|---|---|
| Mr. Samuel N. Hazen | CEO & Director | 1960 |
| Mr. William B. Rutherford | Exec. VP & CFO | 1964 |
| Mr. Charles J. Hall | Pres of National Group | 1953 |
| Mr. Jon Mack Foster | Pres of American Group | 1962 |
| Dr. Michael S. Cuffe M.B.A., M.D. | Exec. VP & Chief Clinical Officer | 1966 |
| Dr. Thomas F. Frist Jr. | Founder & Chairman Emeritus | 1939 |
| Mr. P. Martin Paslick | Sr. VP & Chief Information Officer | 1960 |
| Mr. Frank George Morgan C.F.A. | VP of Investor Relations | NA |
| Ms. Kathleen M. Whalen J.D. | Sr. VP and Chief Ethics & Compliance Officer | 1965 |
| Mr. Michael R. McAlevey | Sr. VP & Chief Legal Officer | 1964 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...